Vincent Louie1, Nyan L Latt2, Derenik Gharibian3, Amandeep Sahota4, Beshoy T Yanny5, Rasham Mittal6, Zoe Bider-Canfield7, T Craig Cheetham8. 1. Ambulatory Care Pharmacist at the Los Angeles Medical Center in CA. vincent.x.louie@kp.org. 2. Gastroenterology Fellow at the Los Angeles Medical Center in CA. latt.nyan@mayo.edu. 3. Clinical Operations Manager for Pharmacy Operations at the Los Angeles Medical Center in CA. derenik.x.gharibian@kp.org. 4. Hepatologist at the Los Angeles Medical Center in CA. amandeep.sahota@kp.org. 5. Gastroenterology Fellow at the Los Angeles Medical Center in CA. beshoy.t.yanny@kp.org. 6. Gastroenterology Fellow at the Los Angeles Medical Center in CA. drrasham@gmail.com. 7. Biostatistician in the Department of Research and Evaluation of Kaiser Permanente Southern California in Pasadena. zoe.bider@kp.org. 8. Researcher in the Department of Research and Evaluation for Kaiser Permanente Southern California in Pasadena.
Abstract
CONTEXT: Traditional hepatitis C virus treatment was limited by low cure rates, side effects, and stringent monitoring requirements. Sofosbuvir, a direct-acting antiviral agent with a cure rate of 96%, was introduced in 2013. However, trials frequently excluded patients with advanced liver disease and prior treatment experience. This study aims to elucidate the real-world cure rates and sofosbuvir safety profile. METHODS: A retrospective cohort study was conducted at Kaiser Permanente Southern California involving patients with hepatitis C virus who received sofosbuvir treatment. Patients age 18 years and older were included, and pregnant patients were excluded. The primary end point was sustained virologic response at 12 weeks posttreatment. Secondary end points were safety and medication adherence. Multiple logistic regression analysis was used to compare patients with genotypes 1 and 2 infections. RESULTS: Of the 213 study patients, 42.3% had cirrhosis, and 38% were treatment-experienced. Most patients (69.5%) received dual therapy (sofosbuvir + ribavirin), whereas the remainder (30.5%) received triple therapy (sofosbuvir + ribavirin + interferon). The overall rate of sustained virologic response at 12 weeks posttreatment rate was 72.9% for genotype 1 infection, 64.7% in the treatment-experienced subgroup, and 66.7% in the cirrhosis subgroup. Rates of sustained virologic response at 12 weeks posttreatment for genotypes 2 and 3 were 90.8% and 55%, respectively. Most patients experienced anemia and fatigue. Women and patients with a lower baseline viral load were statistically more likely to be cured. CONCLUSION: Real-world cure rates were similar to rates seen in clinical trials for genotype 2 infection and lower for genotype 1 infection. Patients with genotype 1 and 3 infection did better with triple therapy compared with dual therapy. Patients tolerated therapy well with side effects, serious adverse events, and discontinuation rates similar to clinical trials. Women and patients with lower baseline hepatitis C viral load were more likely to achieve sustained virological response at 12 weeks posttreatment.
CONTEXT: Traditional hepatitis C virus treatment was limited by low cure rates, side effects, and stringent monitoring requirements. Sofosbuvir, a direct-acting antiviral agent with a cure rate of 96%, was introduced in 2013. However, trials frequently excluded patients with advanced liver disease and prior treatment experience. This study aims to elucidate the real-world cure rates and sofosbuvir safety profile. METHODS: A retrospective cohort study was conducted at Kaiser Permanente Southern California involving patients with hepatitis C virus who received sofosbuvir treatment. Patients age 18 years and older were included, and pregnant patients were excluded. The primary end point was sustained virologic response at 12 weeks posttreatment. Secondary end points were safety and medication adherence. Multiple logistic regression analysis was used to compare patients with genotypes 1 and 2 infections. RESULTS: Of the 213 study patients, 42.3% had cirrhosis, and 38% were treatment-experienced. Most patients (69.5%) received dual therapy (sofosbuvir + ribavirin), whereas the remainder (30.5%) received triple therapy (sofosbuvir + ribavirin + interferon). The overall rate of sustained virologic response at 12 weeks posttreatment rate was 72.9% for genotype 1 infection, 64.7% in the treatment-experienced subgroup, and 66.7% in the cirrhosis subgroup. Rates of sustained virologic response at 12 weeks posttreatment for genotypes 2 and 3 were 90.8% and 55%, respectively. Most patients experienced anemia and fatigue. Women and patients with a lower baseline viral load were statistically more likely to be cured. CONCLUSION: Real-world cure rates were similar to rates seen in clinical trials for genotype 2 infection and lower for genotype 1 infection. Patients with genotype 1 and 3 infection did better with triple therapy compared with dual therapy. Patients tolerated therapy well with side effects, serious adverse events, and discontinuation rates similar to clinical trials. Women and patients with lower baseline hepatitis C viral load were more likely to achieve sustained virological response at 12 weeks posttreatment.
Authors: Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum Journal: Nat Rev Drug Discov Date: 2011-07-01 Impact factor: 84.694
Authors: Eric Delwart; Elizabeth Slikas; Susan L Stramer; Hany Kamel; Debra Kessler; David Krysztof; Leslie H Tobler; Danielle M Carrick; Whitney Steele; Deborah Todd; David J Wright; Steven H Kleinman; Michael P Busch Journal: J Infect Dis Date: 2012-01-31 Impact factor: 5.226
Authors: Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Eric Lawitz; Fred Poordad; Diana M Brainard; Robert H Hyland; Di An; Hadas Dvory-Sobol; William T Symonds; John G McHutchison; Fernando E Membreno Journal: Hepatology Date: 2015-01-30 Impact factor: 17.425
Authors: Sahar Saeed; Erin C Strumpf; Sharon L Walmsley; Kathleen Rollet-Kurhajec; Neora Pick; Valerie Martel-Laferrière; Mark Hull; M John Gill; Joseph Cox; Curtis Cooper; Marina B Klein; Jeff Cohen; Brian Conway; Curtis Cooper; Pierre Côté; Joseph Cox; John Gill; Shariq Haider; Marianne Harris; David Haase; Mark Hull; Julio Montaner; Erica Moodie; Neora Pick; Anita Rachlis; Danielle Rouleau; Roger Sandre; Joseph Mark Tyndall; Marie-Louise Vachon; Sharon Walmsley; David Wong Journal: Clin Infect Dis Date: 2016-01-06 Impact factor: 9.079
Authors: Jihane N Benhammou; Tien S Dong; Folasade P May; Jenna Kawamoto; Ram Dixit; Samuel Jackson; Vivek Dixit; Debika Bhattacharya; Steven B Han; Joseph R Pisegna Journal: Pharmacol Res Perspect Date: 2018-02-22